ACEA Research Grant goes to Teresa Krabbe, Technical University Munich

Teresa Krabbe, PhD student working in the group of Dr. Jennifer Altomonte, Klinikum Rechts der Isar of the Technical University Munich is awarded the recent xCELLigence Research Grant.

Using xCELLigence technology, Teresa Krabbe proposed to develop adoptive T cell therapy as a complimentary immunotherapeutic for an improved oncolytic virus platform.

 

"I am thrilled about the opportunity to work with the xCELLigence to continuously monitor tumor cells infected with our fusogenic oncolytic virus. It will greatly improve our ability to track the morphological changes that occur at very early stages of infection. We are additionally working on a combination of our oncolytic virus platform with TCR T cells and hope to illustrate a synergistic effect in vitro by real time cell analysis with the xCELLigence.”

Teresa Krabbe will be testing the use of adoptively transferred T cell receptor transgenic T (TCR-T) cells as cell carriers to deliver a novel hybrid vector comprising vesicular stomatitis virus (VSV) and Newcastle disease virus (NDV), named rVSV-NDV, and to provide synergistic effector functions. The goals of this study include

 

  • the characterization of the fusogenic oncolytic rVSV-NDV by impedance monitoring, and
  • the evaluation of an innovative strategy combining VSV-NDV with TCR-T as a delivery vehicle for the virus or using the virus to prime the tumor cells for a more effective T cell therapy.

 

Register now for the next Research Grant, find details here:

https://www.aceabio.com/about/grant-program/

 

 
 
 
 

Kommentar schreiben

 

Die mit einem * markierten Felder sind Pflichtfelder.